Erschienen in:
01.05.2019 | Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)
Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
verfasst von:
Carolyn Hall, Vanessa Sarli, Salyna Meas, Anthony Lucci
Erschienen in:
Current Breast Cancer Reports
|
Ausgabe 2/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Liquid biopsies are easily obtainable, non-invasive, longitudinal snapshots that can be used to measure micrometastatic disease burden, monitor disease progression, and provide genomic assessments of primary tumor/metastatic lesions. To date, most published studies have focused on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA); however, the liquid biopsy field is expanding exponentially and new blood components are currently under investigation.
Recent Findings
CTCs and ctDNA remain the most extensively studied liquid biopsy components to date. Several additional blood-based components are the basis of active, ongoing investigations. Some on the horizon include serum/plasma exosomes, platelet-mRNA, miRNA characterization, and global proteomic studies.
Summary
In the era of individualized medicine, liquid biopsy has potential to improve upon current breast cancer management by offering dynamic monitoring possibilities as well as novel targets for therapy.